A silica core, with etched polydopamine NPs loaded with JQ-1, allows for a sustained release pattern of the drug, reducing the expression of PD-L1 on cancer cells and, simultaneously, activating the immune system, as well as reducing the risk of tumor recurrence and metastasis [16]. The gene discussed is CD274; the disease is neoplasm.